Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer
Interventions: BIOLOGICAL: Tislelizumab|DRUG: Nab paclitaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DEVICE: Cyclophosphamide
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: First Affiliated Hospital Xi'an Jiaotong University|Wuhan Union Hospital, China|Beijing Huanxing Cancer Hospital